Literature DB >> 7607717

Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension.

M T Kailasam1, R J Parmer, J H Cervenka, R A Wu, M G Ziegler, B P Kennedy, I A Adegbile, D T O'Connor.   

Abstract

Calcium channel antagonists differ by class in reported frequency of side effects that suggest reflex sympathoadrenal activation. Do such differences result from differential effects on autonomic and baroreflex function? The present study compared acute and chronic effects of two classes of calcium channel antagonists, the dihydropyridine type (felodipine) and the phenylalkylamine type (verapamil), on efferent sympathetic outflow and baroreflex slope in 15 essential hypertensive subjects. Blood pressure, heart rate, hemodynamics, and biochemistries were determined at baseline and after acute (first dose) and chronic (4 weeks) administration of the drugs versus placebo. Acutely, felodipine caused a greater decrease in blood pressure associated with a larger decline in systemic vascular resistance than the corresponding effects produced by verapamil. Chronically, there were similar, significant declines in blood pressure (P = .001) and systemic vascular resistance (P = .001) after each drug. Acutely, increased sympathetic activity after felodipine was suggested by reflex tachycardia (from 69 +/- 3 to 74 +/- 2 beats per minute, P = .014) and elevation of plasma norepinephrine (from 264 +/- 25 to 323 +/- 25 pg/mL, P = .037), whereas after verapamil the corresponding changes were closely similar to those after placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607717     DOI: 10.1161/01.hyp.26.1.143

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

Review 1.  Relevance of heart rate as a risk factor in hypertension.

Authors:  P Palatini; S Julius
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

2.  [Differentiation and evaluation of calcium antagonists in therapy of arterial hypertension].

Authors:  H Holzgreve
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

Review 3.  Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 4.  Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs.

Authors:  P Palatini
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.

Authors:  Richard B R Muijsers; Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy.

Authors:  Paolo Palatini; Athanase Benetos; Stevo Julius
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease.

Authors:  P Palatini
Journal:  Curr Hypertens Rep       Date:  2001-09       Impact factor: 5.369

8.  Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Michael Mancino; Nichole Sanders; Christopher Cargile; J Benjamin Guise; Warren Bickel; W Brooks Gentry
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

Review 9.  Treatment of hypertension in patients with diabetes mellitus : relevance of sympathovagal balance and renal function.

Authors:  Matthias Weck
Journal:  Clin Res Cardiol       Date:  2007-06-27       Impact factor: 5.460

Review 10.  Calcium Channel Blockers in Acute Care: The Links and Missing Links Between Hemodynamic Effects and Outcome Evidence.

Authors:  Jin Wang; David L McDonagh; Lingzhong Meng
Journal:  Am J Cardiovasc Drugs       Date:  2021-01       Impact factor: 3.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.